34 articles
A comprehensive review reveals metformin's polypharmacological mechanisms—from AMPK activation to gut microbiome remodeling—that may delay aging and enhance cancer immunotherapy.
ATX-304 raised resting metabolic rate 8%, slashed triglycerides, and reduced liver fat in an 8-week Phase 1b trial for prediabetes.
A comprehensive review maps berberine's multi-target mechanisms across cancer, neurological, cardiovascular, and metabolic diseases.
A 2025 review reveals how metformin's AMPK activation and mitochondrial effects may slow aging beyond its diabetes role.
Cambrian Bio's ATX-304 combines AMPK and mitochondrial activation in a pill form, with Phase 1b data in prediabetic obese adults due this week.
A comprehensive 2025 review maps berberine's multi-target anti-obesity mechanisms, clinical trial evidence, and strategies to overcome its poor bioavailability.
A molecular brake on AMPK in oligodendrocyte precursors safeguards myelin formation and repair, even when brain glucose is scarce.
Liensinine shifts liver cancer cells from glycolysis to oxidative phosphorylation via AMPK-HIF-1α, reshaping the tumor immune microenvironment.
A 2025 narrative review examines metformin's benefits, risks, and sex-specific efficacy for prediabetic women navigating the menopausal transition.
A comprehensive 2025 review reveals how AMPK orchestrates mitochondrial fission, mitophagy, and biogenesis to restore cellular energy homeostasis.
GLP-1 receptor agonists like semaglutide activate AMPK signaling to reduce amyloid plaques and restore memory in Alzheimer's mouse models.
A lysosome-to-epigenome pathway in C. elegans extends lifespan across multiple generations via histone H3.3 transport from gut to germline.
